Gsa Capital Partners LLP Nuvectis Pharma, Inc. Transaction History
Gsa Capital Partners LLP
- $1.43 Billion
- Q2 2025
A detailed history of Gsa Capital Partners LLP transactions in Nuvectis Pharma, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 39,160 shares of NVCT stock, worth $316,412. This represents 0.02% of its overall portfolio holdings.
Number of Shares
39,160
Previous 34,751
12.69%
Holding current value
$316,412
Previous $340,000
13.82%
% of portfolio
0.02%
Previous 0.03%
Shares
6 transactions
Others Institutions Holding NVCT
# of Institutions
38Shares Held
2.63MCall Options Held
116KPut Options Held
87.6K-
Ronit Capital LLP563KShares$4.55 Million5.37% of portfolio
-
Vanguard Group Inc Valley Forge, PA467KShares$3.78 Million0.0% of portfolio
-
Baldwin Brothers LLC358KShares$2.9 Million0.28% of portfolio
-
Iridian Asset Management LLC254KShares$2.05 Million0.82% of portfolio
-
Geode Capital Management, LLC Boston, MA135KShares$1.09 Million0.0% of portfolio
About Nuvectis Pharma, Inc.
- Ticker NVCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,642,500
- Market Cap $118M
- Description
- Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src...